Drug Trial Radar · NCT03985410
Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers
Last checked: Nov 20, 2026Latest source record: Aug 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
May 23, 2019
Primary completion
Jul 24, 2019
Study completion Jul 24, 2019
Sponsor
- Lead sponsor
- Entasis TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma concentrations on the heart rate-corrected QT interval (QTc).
Conditions
- Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514Drug
intravenous infusion
PlaceboDrug
intravenous infusion
moxifloxacinDrug
oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Placebo-corrected change from Baseline in Fridericia-corrected QTc (QTcF) (ΔΔQTcF)Time frame: Baseline; up to Day 22
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron Clinical Pharmacology Center
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.